Health Canada Requests Labeling Change For All NSAIDs
This article was originally published in The Pink Sheet Daily
The agency will issue guidance to manufacturers on what risk/benefit information should be included in product labeling. Canadian advisory committee recommends uninterrupted marketing of Celebrex, reintroduction of Vioxx and continued marketing prohibition of Bextra.
You may also be interested in...
Health Canada cites increased risk of cardiovascular events associated with Pfizer’s COX-2 inhibitor.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter